O	0	11	Integration	Integration	NN	B-NP
O	12	14	of	of	IN	B-PP
O	15	25	interferon	interferon	NN	B-NP
O	25	26	-	-	HYPH	O
O	26	31	alpha	alpha	SYM	B-NP
O	31	32	/	/	SYM	B-VP
O	32	36	beta	beta	SYM	B-NP
O	37	47	signalling	signalling	NN	B-NP
O	48	50	to	to	TO	B-PP
O	51	54	p53	p53	NN	B-NP
O	55	64	responses	response	NNS	I-NP
O	65	67	in	in	IN	B-PP
B-Cancer	68	74	tumour	tumour	NN	B-NP
O	75	86	suppression	suppression	NN	I-NP
O	87	90	and	and	CC	O
O	91	100	antiviral	antiviral	JJ	B-NP
O	101	108	defence	defence	NN	I-NP
O	108	109	.	.	.	O

O	111	116	Swift	Swift	NN	B-NP
O	117	128	elimination	elimination	NN	I-NP
O	129	131	of	of	IN	B-PP
O	132	143	undesirable	undesirable	JJ	B-NP
B-Cell	144	149	cells	cell	NNS	I-NP
O	150	152	is	be	VBZ	B-VP
O	153	155	an	an	DT	B-NP
O	156	165	important	important	JJ	I-NP
O	166	173	feature	feature	NN	I-NP
O	174	176	in	in	IN	B-PP
B-Cancer	177	183	tumour	tumour	NN	B-NP
O	184	195	suppression	suppression	NN	I-NP
O	196	199	and	and	CC	I-NP
O	200	208	immunity	immunity	NN	I-NP
O	208	209	.	.	.	O

O	210	213	The	The	DT	B-NP
B-Cancer	214	220	tumour	tumour	NN	I-NP
O	221	231	suppressor	suppressor	NN	I-NP
O	232	235	p53	p53	NN	I-NP
O	236	239	and	and	CC	I-NP
O	240	250	interferon	interferon	NN	I-NP
O	250	251	-	-	HYPH	O
O	251	256	alpha	alpha	SYM	B-NP
O	257	260	and	and	CC	O
O	261	262	-	-	HYPH	O
O	262	266	beta	beta	SYM	B-NP
O	267	268	(	(	(	O
O	268	271	IFN	IFN	NN	B-NP
O	271	272	-	-	HYPH	O
O	272	277	alpha	alpha	SYM	B-NP
O	277	278	/	/	SYM	B-VP
O	278	282	beta	beta	SYM	B-NP
O	282	283	)	)	)	O
O	284	287	are	be	VBP	B-VP
O	288	297	essential	essential	JJ	B-ADJP
O	298	301	for	for	IN	B-PP
O	302	305	the	the	DT	B-NP
O	306	315	induction	induction	NN	I-NP
O	316	318	of	of	IN	B-PP
O	319	328	apoptosis	apoptosis	NN	B-NP
O	329	331	in	in	IN	B-PP
B-Cell	332	341	cancerous	cancerous	JJ	B-NP
I-Cell	342	347	cells	cell	NNS	I-NP
O	348	351	and	and	CC	B-PP
O	352	354	in	in	IN	B-PP
O	355	364	antiviral	antiviral	JJ	B-NP
O	365	371	immune	immune	JJ	I-NP
O	372	381	responses	response	NNS	I-NP
O	381	382	,	,	,	O
O	383	395	respectively	respectively	RB	B-ADVP
O	395	396	,	,	,	O
O	397	400	but	but	CC	O
O	401	407	little	little	JJ	B-NP
O	408	410	is	be	VBZ	B-VP
O	411	416	known	know	VBN	I-VP
O	417	422	about	about	IN	B-PP
O	423	428	their	their	PRP$	B-NP
O	429	446	interrelationship	interrelationship	NN	I-NP
O	446	447	.	.	.	O

O	448	452	Here	Here	RB	B-ADVP
O	453	455	we	we	PRP	B-NP
O	456	460	show	show	VBP	B-VP
O	461	465	that	that	IN	B-SBAR
O	466	479	transcription	transcription	NN	B-NP
O	480	482	of	of	IN	B-PP
O	483	486	the	the	DT	B-NP
O	487	490	p53	p53	NN	I-NP
O	491	495	gene	gene	NN	I-NP
O	496	498	is	be	VBZ	B-VP
O	499	506	induced	induce	VBN	I-VP
O	507	509	by	by	IN	B-PP
O	510	513	IFN	IFN	NN	B-NP
O	513	514	-	-	HYPH	O
O	514	519	alpha	alpha	SYM	B-NP
O	519	520	/	/	SYM	B-VP
O	520	524	beta	beta	SYM	B-NP
O	524	525	,	,	,	O
O	526	537	accompanied	accompany	VBN	B-VP
O	538	540	by	by	IN	B-PP
O	541	543	an	an	DT	B-NP
O	544	552	increase	increase	NN	I-NP
O	553	555	in	in	IN	B-PP
O	556	559	p53	p53	NN	B-NP
O	560	567	protein	protein	NN	I-NP
O	568	573	level	level	NN	I-NP
O	573	574	.	.	.	O

O	575	578	IFN	IFN	NN	B-NP
O	578	579	-	-	HYPH	O
O	579	584	alpha	alpha	SYM	B-NP
O	584	585	/	/	SYM	B-VP
O	585	589	beta	beta	SYM	B-NP
O	590	600	signalling	signalling	NN	B-NP
O	601	607	itself	itself	PRP	B-NP
O	608	612	does	do	VBZ	B-VP
O	613	616	not	not	RB	I-VP
O	617	625	activate	activate	VB	I-VP
O	626	629	p53	p53	NN	B-NP
O	629	630	;	;	:	O
O	631	637	rather	rather	RB	B-ADVP
O	637	638	,	,	,	O
O	639	641	it	it	PRP	B-NP
O	642	653	contributes	contribute	VBZ	B-VP
O	654	656	to	to	TO	B-PP
O	657	665	boosting	boost	VBG	B-VP
O	666	669	p53	p53	NN	B-NP
O	670	679	responses	response	NNS	I-NP
O	680	682	to	to	TO	B-PP
O	683	689	stress	stress	NN	B-NP
O	690	697	signals	signal	NNS	I-NP
O	697	698	.	.	.	O

O	699	701	We	We	PRP	B-NP
O	702	706	show	show	VBP	B-VP
O	707	715	examples	example	NNS	B-NP
O	716	718	in	in	IN	B-PP
O	719	724	which	which	WDT	B-NP
O	725	728	p53	p53	NN	B-NP
O	729	733	gene	gene	NN	I-NP
O	734	743	induction	induction	NN	I-NP
O	744	746	by	by	IN	B-PP
O	747	750	IFN	IFN	NN	B-NP
O	750	751	-	-	HYPH	O
O	751	756	alpha	alpha	SYM	B-NP
O	756	757	/	/	SYM	B-NP
O	757	761	beta	beta	SYM	B-NP
O	762	773	contributes	contribute	VBZ	B-VP
O	774	776	to	to	TO	B-PP
B-Cancer	777	783	tumour	tumour	NN	B-NP
O	784	795	suppression	suppression	NN	I-NP
O	795	796	.	.	.	O

O	797	808	Furthermore	Furthermore	RB	B-ADVP
O	808	809	,	,	,	O
O	810	812	we	we	PRP	B-NP
O	813	817	show	show	VBP	B-VP
O	818	822	that	that	IN	B-SBAR
O	823	826	p53	p53	NN	B-NP
O	827	829	is	be	VBZ	B-VP
O	830	839	activated	activate	VBN	I-VP
O	840	842	in	in	IN	B-PP
O	843	850	virally	virally	RB	B-NP
O	851	859	infected	infected	JJ	I-NP
B-Cell	860	865	cells	cell	NNS	I-NP
O	866	868	to	to	TO	B-VP
O	869	874	evoke	evoke	VB	I-VP
O	875	877	an	an	DT	B-NP
O	878	887	apoptotic	apoptotic	JJ	I-NP
O	888	896	response	response	NN	I-NP
O	897	900	and	and	CC	O
O	901	905	that	that	IN	B-SBAR
O	906	909	p53	p53	NN	B-NP
O	910	912	is	be	VBZ	B-VP
O	913	921	critical	critical	JJ	B-ADJP
O	922	925	for	for	IN	B-PP
O	926	935	antiviral	antiviral	JJ	B-NP
O	936	943	defence	defence	NN	I-NP
O	944	946	of	of	IN	B-PP
O	947	950	the	the	DT	B-NP
O	951	955	host	host	NN	I-NP
O	955	956	.	.	.	O

O	957	960	Our	Our	PRP$	B-NP
O	961	966	study	study	NN	I-NP
O	967	974	reveals	reveal	VBZ	B-VP
O	975	976	a	a	DT	B-NP
O	977	985	hitherto	hitherto	RB	I-NP
O	986	998	unrecognized	unrecognized	JJ	I-NP
O	999	1003	link	link	NN	I-NP
O	1004	1011	between	between	IN	B-PP
O	1012	1015	p53	p53	NN	B-NP
O	1016	1019	and	and	CC	I-NP
O	1020	1023	IFN	IFN	NN	I-NP
O	1023	1024	-	-	HYPH	O
O	1024	1029	alpha	alpha	SYM	B-NP
O	1029	1030	/	/	SYM	B-VP
O	1030	1034	beta	beta	NN	B-NP
O	1035	1037	in	in	IN	B-PP
B-Cancer	1038	1044	tumour	tumour	NN	B-NP
O	1045	1056	suppression	suppression	NN	I-NP
O	1057	1060	and	and	CC	O
O	1061	1070	antiviral	antiviral	JJ	B-NP
O	1071	1079	immunity	immunity	NN	I-NP
O	1079	1080	,	,	,	O
O	1081	1086	which	which	WDT	B-NP
O	1087	1090	may	may	MD	B-VP
O	1091	1095	have	have	VB	I-VP
O	1096	1107	therapeutic	therapeutic	JJ	B-NP
O	1108	1120	implications	implication	NNS	I-NP
O	1120	1121	.	.	.	O

